Life Expectancy after Initiation of Combination Antiretroviral Therapy in Thailand

Teeraananchai, Sirinya; Chaivooth, Suchada; Kerr, Stephen J.; Bhakeecheep, Sorakij; Avihingsanon, Anchalee; Teeraratkul, Achara; Sirinirund, Petchsri; Law, Matthew; Ruxrungtham, Kiat

doi:10.3851/imp3121

Cited by 20 publications

(15 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This indicator reflects individuals’ health status and can be used to assess the effectiveness of plans and interventions [7-9,11]. Although many studies have found AIDS to have a significant effect on longevity in various communities [9,12-14], the available information on the health status of HIV/AIDS patients in Iran, including life expectancy, is not very clear. Therefore, to increase our knowledge of the effect of AIDS on life expectancy in Iranian patients, and to assess the effectiveness of antiretroviral interventions, we need to obtain this information.…”

Section: Introductionmentioning

confidence: 99%

Life expectancy of HIV-positive patients after diagnosis in Iran from 1986 to 2016: A retrospective cohort study at national and sub-national levels

et al. 2018

View full text Add to dashboard Cite

OBJECTIVESLittle is known about the life expectancy of individuals with human immunodeficiency virus (HIV) in Iran. This study therefore aimed to estimate the life expectancy of HIV-positive patients in Iran.METHODSIn this retrospective cohort study, we extracted data from the Center for Disease Control and Prevention of the Ministry of Health and Medical Education and the Death Registration System. We included patients aged 20 years and older who had a specified date of diagnosis. We estimated life expectancy and its 95% confidence intervals (CIs) using Chiang’s methodology.RESULTSThe overall life expectancy at the national level was 23.1 years (95% CI, 22.6 to 23.5). Life expectancy was 21.6 years (95% CI, 21.1 to 22.0) for men and 32.7 years (95% CI, 31.4 to 34.0) for women. The life expectancy of patients who did or did not receive antiretroviral therapy (ART) was 37.0 years (95% CI, 36.2 to 37.8) and 15.5 years (95% CI, 15.1 to 15.9), respectively. The life expectancy of patients with or without tuberculosis (TB) was 21.6 years (95% CI, 20.4 to 22.9) and 36.5 years (95% CI, 35.7 to 37.4), respectively.CONCLUSIONSThe life expectancy of Iranian HIV-positive patients was found to be very low. To improve their longevity, improvements in ART coverage and the control and treatment of TB are advised.

show abstract

Section: Introductionmentioning

confidence: 99%

Life expectancy of HIV-positive patients after diagnosis in Iran from 1986 to 2016: A retrospective cohort study at national and sub-national levels

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In Thailand, the Thai Ministry of Public Health launched the National Access to Antiretroviral Program for People Living with HIV/AIDS (NAPHA) in 2002, making ART available to the majority of HIV‐infected patients. As a result, the life expectancy of PLWHA in Thailand increased, similar to experiences in other countries world‐wide . Many of these individuals are now reaching middle and older age (defined as PLWHA who are ≥ 50 years old).…”

Section: Introductionmentioning

confidence: 66%

Peripheral artery disease in HIV‐infected older adults on antiretroviral treatment in Thailand

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Although most of the programmes in the Asia-Pacific region relied on active follow-up to ascertain outcomes, it is unclear how consistently it was applied, with the result that there may be some underestimation of mortality rates. However, data from Thailand and Indonesia suggest that deaths after LTFU account for a relatively small fraction of total deaths in these settings [54,55], and other studies from North America and Latin America have found only modest differences in mortality between programmes that employ active follow-up and those that rely on linkage to vital registration systems [9,24]. Another limitation is that we have pooled data across IeDEA regions rather than fitting separate regression models for each region, which may have led to some inter-regional differences in covariate effects being obscured.…”

Section: Discussionmentioning

confidence: 99%

Global variations in mortality in adults after initiating antiretroviral treatment

Johnson

Anderegg

Zaniewski

et al. 2019

Aids

View full text Add to dashboard Cite

a,b , for the International epidemiology Databases to Evaluate AIDS (IeDEA) Collaboration Background: UNAIDS models use data from the International epidemiology Databases to Evaluate AIDS (IeDEA) collaboration in setting assumptions about mortality rates after antiretroviral treatment (ART) initiation. This study aims to update these assumptions with new data, to quantify the extent of regional variation in ART mortality and to assess trends in ART mortality. Methods: Adult ART patients from Africa, Asia and the Americas were included if they had a known date of ART initiation during 2001-2017 and a baseline CD4 þ cell count. In cohorts that relied only on passive follow-up (no patient tracing or linkage to vital registration systems), mortality outcomes were imputed in patients lost to follow-up based on a meta-analysis of tracing study data. Poisson regression models were fitted to the mortality data. Results: 464 048 ART patients were included. In multivariable analysis, mortality rates were lowest in Asia and highest in Africa, with no significant differences between African regions. Adjusted mortality rates varied significantly between programmes within regions. Mortality rates in the first 12 months after ART initiation were significantly higher during 2001-2006 than during 2010-2014, although the difference was more substantial in Asia and the Americas [adjusted incidence rate ratio (aIRR) 1.43, 95% CI: 1.22-1.66] than in Africa (aIRR 1.07, 95% CI: 1.04-1.11).

show abstract

Life Expectancy after Initiation of Combination Antiretroviral Therapy in Thailand

Abstract: Increasing life expectancy with higher baseline CD4 T-cell counts supports the guideline recommendations to start cART irrespective of CD4 T-cell count. These results are beneficial to forecast the treatment cost and develop health policies for people living with HIV in Thailand and Asia.

Cited by 20 publications

References 15 publications

Life expectancy of HIV-positive patients after diagnosis in Iran from 1986 to 2016: A retrospective cohort study at national and sub-national levels

Life expectancy of HIV-positive patients after diagnosis in Iran from 1986 to 2016: A retrospective cohort study at national and sub-national levels

Peripheral artery disease in HIV‐infected older adults on antiretroviral treatment in Thailand

Global variations in mortality in adults after initiating antiretroviral treatment

Contact Info

Product

Resources

About